Asia-Pacific
IP lawyers at three firms reflect on how courts across Australia have reacted to AI use in litigation, and explain why they support measured use of the technology
Tilleke & Gibbins topped the leaderboard with four awards across the region, while Anand & Anand and Kim & Chang emerged as outstanding domestic firms
Andrew Blattman, who helped IPH gain significant ground in Asia and Canada, will leave in the second half of 2026
Vivien Chan joins us for our ‘Women in IP’ series to discuss gender bias in the legal profession and why the business model followed by law firms leaves little room for women leaders
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsEarly adaptation to manage an unpredictable transition is vital, say Linh Duy Mai, Giang Hoang Bach, and Diep Thi Bich Le of T&G Law Firm LLC (TGVN), the local associate of Tilleke & Gibbins -
Sponsored by Saint Island International Patent & Law OfficesTony Tung-Yang Chang of Saint Island International Patent & Law Offices says plant variety holders will have welcomed the ruling, which resolves previous divergence in local courts over the methodology for assessing infringement
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Eeshani Sharma of RNA, Technology and IP Attorneys explain how India’s legal framework applies to video game characters and question whether it needs to ‘level up’, given the industry’s rapid evolution
-
Sponsored by Uni-intel Patent and Trademark Law FirmGump Wang of Uni-intel Patent and Trademark Law Firm explores the strategic value of utility models, which have strong enforcement potential and play a crucial role in China’s patent system
-
Sponsored by AFD China Intellectual Property Law OfficeLinlin Sun and Xia Zheng of AFD China Intellectual Property Law Office cite two key Chinese Supreme People’s Court cases to clarify the conditions under which supplementary experimental data is accepted
-
Sponsored by DEQI Intellectual Property Law CorporationChen Shihua of DEQI Intellectual Property Law Corporation explains China's patent term compensation system, which includes a patent term adjustment for delays and a patent term extension for pharmaceutical patents requiring regulatory approval
